“…Precedent for the development of FH binding protein‐based vaccines is well‐established. The type B meningococcal vaccines, Bexsero ® (GlaxoSmithKline) and Trumenba ® (Pfizer) (Beeslaar, Absalon, et al., 2020; Beeslaar, Peyrani, et al., 2020; Borrow et al., 2020) both employ wild‐type FH binding proteins . Beernink and colleagues have demonstrated that site‐directed mutations introduced into FHbp that decrease FH binding resulted in superior complement‐mediated serum anti‐FHbp bactericidal responses than wild‐type FHbp in human FH transgenic mice (Beernink, Shaughnessy, et al, 2011; Beernink, Shaughnessy, et al, 2012and rhesus macaques 2016; Beernink, Vianzon, et al, 2019.…”